- Home
- SPFI vs ANNX Comparison
SPFI vs ANNX Comparison
Compare SPFI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | ANNX |
|---|---|---|
| Founded | 1941 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.4M | 730.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPFI | ANNX |
|---|---|---|
| Price | $41.93 | $5.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $44.00 | $16.50 |
| AVG Volume (30 Days) | 61.5K | ★ 2.1M |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ 42.94 |
| EPS | ★ 2.55 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.65 | N/A |
| Revenue Next Year | $9.40 | N/A |
| P/E Ratio | $16.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.01 | $1.29 |
| 52 Week High | $44.00 | $7.18 |
Technical Indicators
Market Signals| Indicator | SPFI | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 53.10 |
| Support Level | $41.33 | $4.69 |
| Resistance Level | $43.75 | $7.18 |
| Average True Range (ATR) | 1.12 | 0.31 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 39.98 | 84.74 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.